A Shot for the Mind: How the Shingles Vaccine May Shield Against Dementia
A large-scale observational study of over 1.5 million US Medicare beneficiaries aged 65 and older has revealed a compelling association: receipt of the recombinant zoster vaccine (RZV) is linked to a substantially reduced risk of developing new-onset dementia. Over a three-year follow-up period, vaccinated individuals showed a 33% lower incidence of all-cause dementia compared to unvaccinated peers, with similarly robust reductions observed for Alzheimer’s disease and vascular dementia. The findings add to a growing body of evidence suggesting that common viral infections—and the immune responses they provoke—may play a greater role in neurodegenerative processes than previously recognized.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
